Q1 2024 Summary
Published Jan 31, 2025, 2:36 AM UTC- Revenue growth is expected in upcoming quarters, driven by increases in digital health revenue and technology-enabled solutions, as well as improved customer retention.
- The company is launching new AI products like cirrusAI Notes, which are expected to contribute to revenue in the second half of the year.
- The company has identified $22 million in annualized cost reductions, with $15 million in in-year savings for 2024, improving profitability and free cash flow.
- Suspension of Preferred Stock Dividends Due to Financial Constraints: The company suspended its preferred stock dividends because the bank indicated that continued payments would prevent relaxation of covenants on their line of credit. This suggests financial constraints and may indicate tight liquidity or financial stress.
- Revenue Growth Uncertainty and Reliance on Unproven AI Products: The company is relying on new AI products like cirrusAI Notes to drive future revenue growth. However, these products are still in pilot testing, and the company acknowledges it's hard to predict how much revenue they will generate, indicating uncertainty in growth prospects.
- Softness in Med SR Revenue and Emphasis on Cost Cutting Over Growth: Med SR's nonrecurring project revenue continues to be soft, with expectations that second-quarter revenue will be similar to the first quarter. The company is focusing heavily on cost reductions, identifying $22 million in annualized cuts, which may impact future growth and suggests potential challenges in increasing revenue.
-
Unsolicited Offer and Capital Structure
Q: Details on yesterday's press release?
A: The company received an unsolicited indication of interest from a leading PE fund. The Board decided to disclose it and hired Citizens JMP to analyze the capital structure and potential changes. The offer differentiated the treatment between the Series A and Series B preferred shares in a change of control, and the Board aims to address this disparity. -
Line of Credit and Dividend Suspension
Q: Comments on the line of credit?
A: The company has an $8 million balance on a $20 million line of credit with SVB. In December, they suspended the preferred stock dividend to focus on reducing expenses and achieving positive free cash flow. They identified approximately $22 million in annualized cost reductions, with 2024 expected savings of $15 million, equal to their annual dividend. They plan to continue repaying the line from cash flow and will consider reinstating the dividend after several more months of positive cash flow. -
Revenue Growth Guidance
Q: Why will revenue grow each quarter?
A: Revenue is expected to increase due to growth in digital health offerings, where revenue increased by roughly 4x year-over-year. Additional growth will come from RCM and technology-enabled solutions. AI products and services may contribute to revenue in the second half. -
Cost Reduction and Competitive Advantages
Q: Examples of cost takeouts?
A: The company has identified $22 million in annualized cost savings, including about $7 million related to IT and R&D. They are eliminating redundancies and reducing costs by leveraging their fully integrated team and technological capabilities. They aim to cut expenses without impacting clients or near-term revenue. -
Med SR Revenue and Opportunities
Q: How will Med SR improve revenue?
A: Med SR's revenue drivers include RCM services, where revenue increased by roughly 300% compared to acquisition level. They continue to work with Meditech, with revenue growing over the last two years. Growth depends on Meditech's own expansion. They see opportunities in generative AI products, but are focusing primarily on generating free cash flow. -
cirrusAI Notes Product Launch
Q: Details on cirrusAI Notes?
A: cirrusAI Notes is a product that listens to patient-provider conversations and converts them into notes instantaneously. It can be a pure technology play or combined with services where team members edit notes. The initial target market is the existing client base. -
CareCloud Wellness and PRIME Updates
Q: Updates on CareCloud Wellness and PRIME?
A: CareCloud Wellness revenue increased by almost 4x from Q1 2023 to Q1 2024. They continue to onboard more patients and practices, seeing momentum in revenue growth. CareCloud PRIME is being moved into production, with ongoing onboarding and transitioning of clients to the new platform. -
Share Count and 10-Q Filing
Q: When is the 10-Q filing, and share count?
A: The 10-Q will be filed tonight at 4:30 PM after market close. The current common shares outstanding are 16.1 million. -
Reinstating Preferred Dividend
Q: Plans to reinstate preferred dividend?
A: The company wants to see several more months of positive cash flow that would cover the dividends before discussing reinstating the dividend. They paid down $2 million on the line of credit, with the balance now at $8 million. -
Restructuring Charges
Q: Additional restructuring charges expected?
A: They estimate about another $400,000 in restructuring charges for the remainder of the year.